Form 4: Recursion Pharma Director Sells 40,000 Shares

Christopher Gibson, a director at Recursion Pharmaceuticals, sold 40,000 shares of Class A Common Stock for $4.47 per share as part of a pre-arranged 10b5-1 trading plan.

Summary

• Christopher Gibson, a director at Recursion Pharmaceuticals, Inc. (RXRX), reported transactions on January 20, 2026.
• He acquired 40,000 shares of Class A Common Stock at a price of $0, likely through the conversion of Class B Common Stock.
• Concurrently, he disposed of 40,000 shares of Class A Common Stock at a price of $4.47 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on May 12, 2025.
• Following these transactions, Gibson directly beneficially owns 913,839 shares of Class A Common Stock.
• He also holds significant derivative securities, including 4,623,334 shares of Class B Common Stock directly, and additional Class B shares indirectly through LAHWRAN-3 LLC (386,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (50,000 shares).
• Gibson holds various stock options to buy Class A Common Stock with exercise prices ranging from $2.48 to $11.40, with different vesting schedules and expiration dates up to February 3, 2035.

Sentiment

Score: 5

Explanation: The sale of shares by a director, even under a 10b5-1 plan, can be viewed with slight caution by the market. However, the pre-planned nature mitigates immediate negative implications, and the director retains substantial holdings. The sale price of $4.47 is below some option exercise prices, which could be a minor concern.

Positives

• The sale was executed under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not necessarily a reaction to recent negative company news.
• The director retains a substantial beneficial ownership in the company, including over 900,000 Class A shares and millions of convertible Class B shares and stock options.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces insider ownership.
• The sale price of $4.47 per share is relatively low compared to some of the option exercise prices, suggesting the stock might be trading below previous highs.

Future Outlook

NA

Industry Context

This Form 4 filing is specific to an insider transaction and does not provide broader industry context or trends for Recursion Pharmaceuticals or the biotechnology sector. Insider sales, even pre-planned, are routinely monitored by investors for sentiment.

Related Party Transactions

• Christopher Gibson indirectly holds Class B Common Stock through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust, where he is a member/manager or trustee. These are related party holdings.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be interpreted as a slight negative signal, though the 10b5-1 plan mitigates this. The director still holds a significant stake, aligning his interests with shareholders.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this insider transaction report.

Key Dates

Recommendation

The filing reports a pre-scheduled insider sale, which is a routine event for directors managing their personal portfolios. While a sale reduces insider ownership, the 10b5-1 plan indicates it's not based on new, non-public information. The director retains substantial holdings, suggesting continued alignment with the company's long-term prospects. Without additional financial or operational context, this Form 4 alone does not warrant a change from a "hold" position, as it doesn't present new fundamental insights into the company's performance or strategic direction.

Keywords

Recursion Pharmaceuticals, RXRX, Insider Trading, Form 4, Stock Sale, Director Transaction, Christopher Gibson, 10b5-1 Plan, Class A Common Stock, Class B Common Stock, Stock Options